Select Language:
A Chinese biotech company specializing in radiopharmaceuticals has successfully raised 1 billion yuan (approximately US$145.3 million) to advance its pipeline through clinical trials and to support research, development, and manufacturing of medical isotopes. The Series E funding round was led by a venture capital firm affiliated with a major state-owned investment entity, along with support from a prominent local investment and its existing shareholder.
This company operates within the nuclear medicine field, utilizing minute radioactive substances—radiopharmaceuticals—to diagnose and treat conditions like cancer. The newly acquired funds aim to solidify its leadership position in the domestic market for medical isotopes and radiopharmaceuticals.
The company’s chairman expressed confidence that with strong investor backing, the local isotope industry can reach new heights. He added that the raised capital will primarily enhance the company’s core development activities.
Investors see significant promise in radiopharmaceuticals as a key component of precision medicine. They highlighted that the company has demonstrated substantial clinical value through its innovative technology platform and product pipeline.
The investment partner emphasized that both funding and collaborative industry efforts will be instrumental in advancing self-sufficient core technologies, reinforcing the sector’s ecosystem, boosting Shanghai’s role in radiopharmaceutical innovation, and supporting broader national health initiatives.
This aligns with China’s “Healthy China 2030” plan, a comprehensive strategy initiated in 2016 that aims to prioritize public health through a shift from disease treatment to prevention.
ChatGPT
Perplexity
Gemini AI
Grok AI
